Drug intelligence / Profile preview

FRE02

Development stage: Preclinical
Lead developer: Freya Biosciences
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics

Overview

FRE02 appears to be an internal Freya Biosciences development code associated with a proposed microbial immunotherapy program for bacterial vaginosis, but I could not verify a distinct public drug record for this exact code. Freya Biosciences publicly describes a women’s health pipeline built on its Dyscover platform and states that its bacterial-vaginosis-associated program is FB401, a first-in-class candidate intended to modulate the vaginal microbiome and local immune/inflammatory responses; however, the exact relationship between FRE02 and any named public asset is not clearly documented in accessible sources. Because the specific identity, composition, and mechanism of FRE02 are not independently confirmed, this entry should be treated as an unverified code-name-level record rather than a fully established drug profile.

Beyond the preview

Go deeper on FRE02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FRE02.

Explore the full profile